XOMA Royalty (XOMA) to Release Earnings on Tuesday

XOMA Royalty (NASDAQ:XOMA) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $9.39 million for the quarter.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.32. The company had revenue of $15.91 million during the quarter, compared to the consensus estimate of $6.75 million. XOMA Royalty had a negative net margin of 13.04% and a negative return on equity of 12.43%. On average, analysts expect XOMA Royalty to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

XOMA Royalty Stock Up 2.6%

Shares of NASDAQ XOMA opened at $26.50 on Friday. The business has a 50-day moving average of $25.89 and a two-hundred day moving average of $24.22. The company has a market capitalization of $317.21 million, a price-to-earnings ratio of -23.04 and a beta of 1.00. XOMA Royalty has a 1 year low of $18.35 and a 1 year high of $35.00. The company has a debt-to-equity ratio of 1.18, a current ratio of 5.54 and a quick ratio of 5.54.

Insider Activity

In other XOMA Royalty news, major shareholder Bvf Partners L. P/Il sold 392,723 shares of the business’s stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $27.10, for a total value of $10,642,793.30. Following the completion of the sale, the insider owned 1,267,545 shares in the company, valued at approximately $34,350,469.50. The trade was a 23.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Owen Hughes sold 25,637 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $25.38, for a total value of $650,667.06. Following the completion of the sale, the chief executive officer directly owned 62,701 shares of the company’s stock, valued at $1,591,351.38. The trade was a 29.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.10% of the stock is currently owned by insiders.

Institutional Trading of XOMA Royalty

An institutional investor recently raised its position in XOMA Royalty stock. Geode Capital Management LLC raised its holdings in XOMA Royalty Corporation (NASDAQ:XOMA) by 9.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 203,601 shares of the biotechnology company’s stock after purchasing an additional 16,929 shares during the quarter. Geode Capital Management LLC owned about 1.70% of XOMA Royalty worth $5,132,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $104.00 target price on shares of XOMA Royalty in a research note on Wednesday, May 28th. Benchmark assumed coverage on shares of XOMA Royalty in a research report on Thursday, April 17th. They set a “buy” rating and a $35.00 price objective for the company. Finally, Wall Street Zen cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Sunday, August 3rd.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.